ATNM Stock Forecast 2025-2026
Distance to ATNM Price Targets
ATNM Price Momentum
10 Quality Stocks Worth Considering Now
Researching Actinium (ATNM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ATNM and similar high-potential opportunities.
Latest ATNM Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, ATNM has a bullish consensus with a median price target of $5.00 (ranging from $2.00 to $9.00). Currently trading at $1.21, the median forecast implies a 313.2% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATNM Analyst Ratings
ATNM Price Target Range
Latest ATNM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATNM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 27, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 18, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Nov 19, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $5.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $4.00 |
| Aug 6, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
| Jun 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
| May 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
| May 14, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Initiates | $25.00 |
| May 2, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
| Apr 30, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $21.00 |
| Apr 29, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
| Apr 1, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $21.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
| Mar 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $50.00 |
Actinium Pharmaceuticals Inc. (ATNM) Competitors
The following stocks are similar to Actinium based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Actinium Pharmaceuticals Inc. (ATNM) Financial Data
Actinium Pharmaceuticals Inc. has a market capitalization of $37.75M with a P/E ratio of -1.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -110.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Actinium Pharmaceuticals Inc. (ATNM) Business Model
About Actinium Pharmaceuticals Inc.
Develops targeted therapies for cancer treatment.
Actinium Pharmaceuticals operates as a clinical-stage biopharmaceutical company that focuses on creating innovative therapies using radioisotopes and proprietary tumor-targeting agents. The company generates revenue through collaborations with research institutions and potentially through future product sales after successful clinical trials and regulatory approvals.
Actinium specializes in targeted radiotherapy, particularly for hematologic malignancies like acute myeloid leukemia. The company is positioned in a growing niche within personalized medicine and emphasizes improving patient outcomes through its flagship Antibody Radiation-Conjugates (ARCs) platform.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
37
CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Country
United States
IPO Year
2012
Website
www.actiniumpharma.comActinium Pharmaceuticals Inc. (ATNM) Latest News & Analysis
A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (NYSE: ATNM) and some of its officers, as announced by Bronstein, Gewirtz & Grossman, LLC.
A class action lawsuit against Actinium Pharmaceuticals may lead to financial liability, reputational damage, and stock price volatility, impacting investor confidence and decisions.
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investors who experienced losses may explore potential recovery options under federal securities laws. Further details can be found in the provided link.
Legal actions can signal potential financial instability or mismanagement within a company, impacting stock prices and investor confidence in Actinium Pharmaceuticals.
A class action lawsuit has been filed against Actinium Pharmaceuticals (NYSE: ATNM) for alleged federal securities law violations affecting investors from March 31, 2022, to August 2, 2024.
A class action lawsuit against Actinium Pharmaceuticals may indicate potential financial and reputational risks, impacting stock performance and investor confidence in the company.
Investors in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) who experienced losses may explore recovery options under federal securities laws. More info available through the provided link.
Potential legal action against Actinium Pharmaceuticals may indicate financial instability or governance issues, impacting stock performance and investor confidence.
Investors in Actinium Pharmaceuticals (NYSE: ATNM) who incurred losses may explore potential recovery options under federal securities laws. More info is available via the provided link.
The news indicates potential legal action regarding Actinium Pharmaceuticals, which could impact stock performance and investor sentiment if losses are pursued.
Investors in Actinium Pharmaceuticals (NYSE:ATNM) who experienced losses may explore recovery options under federal securities laws. More information is available through the provided link.
A potential lawsuit regarding Actinium Pharmaceuticals could lead to financial recoveries for affected investors, impacting the company's stock performance and investor sentiment.
Frequently Asked Questions About ATNM Stock
What is Actinium Pharmaceuticals Inc.'s (ATNM) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Actinium Pharmaceuticals Inc. (ATNM) has a median price target of $5.00. The highest price target is $9.00 and the lowest is $2.00.
Is ATNM stock a good investment in 2025?
According to current analyst ratings, ATNM has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATNM stock?
Wall Street analysts predict ATNM stock could reach $5.00 in the next 12 months. This represents a 313.2% increase from the current price of $1.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Actinium Pharmaceuticals Inc.'s business model?
Actinium Pharmaceuticals operates as a clinical-stage biopharmaceutical company that focuses on creating innovative therapies using radioisotopes and proprietary tumor-targeting agents. The company generates revenue through collaborations with research institutions and potentially through future product sales after successful clinical trials and regulatory approvals.
What is the highest forecasted price for ATNM Actinium Pharmaceuticals Inc.?
The highest price target for ATNM is $9.00 from at , which represents a 643.8% increase from the current price of $1.21.
What is the lowest forecasted price for ATNM Actinium Pharmaceuticals Inc.?
The lowest price target for ATNM is $2.00 from at , which represents a 65.3% increase from the current price of $1.21.
What is the overall ATNM consensus from analysts for Actinium Pharmaceuticals Inc.?
The overall analyst consensus for ATNM is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are ATNM stock price projections?
Stock price projections, including those for Actinium Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.